These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 38057186

  • 1. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Gonzalez-Mosquera LF, Rous FA, Rogers A, Smith N, Goyert G, Gadgeel S.
    Clin Lung Cancer; 2024 Mar; 25(2):e77-e80. PubMed ID: 38057186
    [Abstract] [Full Text] [Related]

  • 2. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z, Wu R, Li C, Cheng K, Di Y, Lv T, Liu H, Song Y.
    Anticancer Drugs; 2023 Nov 01; 34(10):1069-1075. PubMed ID: 36688904
    [Abstract] [Full Text] [Related]

  • 3. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T, Hida T, Yatabe Y.
    Anticancer Drugs; 2016 Jul 01; 27(6):573-5. PubMed ID: 26938871
    [Abstract] [Full Text] [Related]

  • 4. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
    Lin J, Wang W, Lin J, Chen R, Cao Y.
    J Cell Mol Med; 2022 Oct 01; 26(20):5326-5329. PubMed ID: 36102237
    [Abstract] [Full Text] [Related]

  • 5. Treating anaplastic lymphoma kinase (ALK) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy.
    Wu F, Rittberg R, Lim K, Ho C.
    BMJ Case Rep; 2024 Mar 25; 17(3):. PubMed ID: 38531551
    [Abstract] [Full Text] [Related]

  • 6. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M, An Z, Tang Q, Ma Y, Yan J, Chen S, Wang Y.
    J Cell Mol Med; 2021 Oct 25; 25(19):9476-9481. PubMed ID: 34541785
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
    Yin Q, Guo T, Zhou Y, Sun L, Meng M, Ma L, Wang X.
    Thorac Cancer; 2022 Feb 25; 13(4):637-642. PubMed ID: 34964276
    [Abstract] [Full Text] [Related]

  • 8. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S, Shi C, Zhang H, Li J.
    Medicine (Baltimore); 2021 Dec 23; 100(51):e27999. PubMed ID: 34941039
    [Abstract] [Full Text] [Related]

  • 9. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayama K, Nakanishi Y.
    Invest New Drugs; 2015 Oct 23; 33(5):1148-50. PubMed ID: 26334220
    [Abstract] [Full Text] [Related]

  • 10. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K.
    Clin Lung Cancer; 2016 Nov 23; 17(6):528-534. PubMed ID: 27318655
    [Abstract] [Full Text] [Related]

  • 11. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N, Nakashima K, Naito T, Nakajima T, Endo M, Takahashi T.
    BMC Cancer; 2017 Jul 06; 17(1):471. PubMed ID: 28683775
    [Abstract] [Full Text] [Related]

  • 12. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X, Liao Q, Yang Q, Chen L, Xiao M, Cheng Y.
    Invest New Drugs; 2022 Aug 06; 40(4):850-853. PubMed ID: 35441911
    [Abstract] [Full Text] [Related]

  • 13. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
    Lin X, Yang X, Tan Y, Duan Q, He M.
    Invest New Drugs; 2022 Oct 06; 40(5):1160-1163. PubMed ID: 35608716
    [Abstract] [Full Text] [Related]

  • 14. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
    Koyama K, Katsurada N, Jimbo N, Tachihara M, Tamura D, Nakata K, Nagano T, Yamamoto M, Kamiryo H, Kobayashi K, Itoh T, Nishimura Y.
    Pathol Int; 2019 May 06; 69(5):294-299. PubMed ID: 30900377
    [Abstract] [Full Text] [Related]

  • 15. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z, Li P, Yan B, Gao Q, Jiang X, Zhan Z, Yan Q, Lizaso A, Huang C.
    Thorac Cancer; 2020 Jan 06; 11(1):176-180. PubMed ID: 31766077
    [Abstract] [Full Text] [Related]

  • 16. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V, Ou SH.
    Expert Opin Drug Saf; 2017 Apr 06; 16(4):509-514. PubMed ID: 28276856
    [Abstract] [Full Text] [Related]

  • 17. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y, Yamamoto N, Masters ET, Kikkawa H, Mardekian J, Wiltshire R, Togo K, Ohe Y.
    Adv Ther; 2020 Jul 06; 37(7):3311-3323. PubMed ID: 32472430
    [Abstract] [Full Text] [Related]

  • 18. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N.
    Lung Cancer; 2016 Sep 06; 99():66-8. PubMed ID: 27565916
    [Abstract] [Full Text] [Related]

  • 19. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Liu D, Xu X, Wen J, Zhang C, Fan M.
    Lung Cancer; 2021 Oct 06; 160():32-35. PubMed ID: 34391065
    [Abstract] [Full Text] [Related]

  • 20. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K, Hataji O, Kobayashi H, Fujiwara A, Yoshida M, D'Alessandro-Gabazza CN, Itani H, Tanigawa M, Ikeda T, Fujiwara K, Fujimoto H, Kobayashi T, Gabazza EC, Taguchi O, Yamamoto N.
    J Thorac Oncol; 2017 Feb 06; 12(2):390-396. PubMed ID: 27498387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.